Abstract P3-12-04: RAD51 135G>C Does Not Modify Breast Cancer Risk in Non-BRCA1/2 Mutation Carriers: Evidence from a Meta-Analysis of 12 Studies

K-D Yu,Z-M Shao

DOI: https://doi.org/10.1158/0008-5472.sabcs10-p3-12-04

IF: 11.2

2010-01-01

Cancer Research

Abstract:A single-nucleotide polymorphisms (SNP) in the 59-untranslated region (UTR) of RAD51, 135G>C (rs1801320), was reported to be associated with an increased risk of breast cancer among BRCA2 as well as BRCA1 carriers. A few studies have also investigated the genetic contribution of RAD51 135G>C to the risk of sporadic breast cancers or breast cancer in non-BRCA1/2 carriers, though the results are yet controversial andinconclusive. We in this study performed a more precise estimation of the relationship between 135G>C and breast cancer among non-BRCA1/2 mutation carriers by meta-analyzing the currently available evidence from literature. A total of 12 studies involving 7,065 cases and 6,981 controls were identified. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. When all the studies were pooled into the meta-analysis, there was no evidence for a significant association between 135G>C and breast cancer risk in non-BRCA1/2 mutation carriers (for CC vs. GG: OR = 0.995, 95% CI: 0.741-1.336; for GC vs. GG: OR = 0.959, 95% CI: 0.869-1.057; for dominant model: OR = 0.988, 95% CI: 0.902-1.082; and for recessive model: OR = 1.037, 95% CI: 0.782-1.376). We also performed subgroup analysis by ethnicity (Caucasian) as well as did analysis using the studies fulfilling Hardy-Weinberg equilibrium, and the results did not change. In summary, the present meta-analysis suggests that the RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-12-04.